Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/49431| Title: | Emerging treatments for Leber hereditary optic neuropathy and retinitis pigmentosa |
| Authors: | Zuccarelli, Marta Borg, John-Joseph Vella Szijj, Janis Serracino-Inglott, Anthony |
| Keywords: | Optic Atrophy, Hereditary, Leber -- Chemotherapy -- European Union countries Retinitis pigmentosa -- Chemotherapy -- European Union countries Rare diseases -- Genetic aspects |
| Issue Date: | 2019-09 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Zuccarelli, M., Borg, J. J., Vella-Szijj, J., & Serracino-Inglott, A. (2019, September). Emerging treatments for Leber hereditary optic neuropathy and retinitis pigmentosa. Poster session presented at the FIP World Congress of Pharmacy and Pharmaceutical Sciences, Abu Dhabi, United Arab Emirates. |
| Abstract: | A poster presentation regarding emerging treatments for Leber hereditary optic neuropathy and retinitis pigmentosa. Introduction: Leber Hereditary Optic Neuropathy (LHON) and Retinitis Pigmentos (RP) are rare-inherited diseases causing blindness with few treatments available within the European Union (EU). Raxon (idebenone) is the only approved medicinal product (MP) to treat LHON. Luxturna (voretigene neparvovec) is the only approved MP to treat RP. Aims: To understand emerging patterns pursued by pharmaceutical companies when developing medicinal products to treat LHON and RP. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/49431 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Emerging_treatments_for_Leber_hereditary_optic_neuropathy_and_retinitis_pigmentosa_2019.pdf | 277.25 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.